Evaluation of Vav3.1 as prognostic marker in endometrial cancer.
Maximilian BoeschSieghart SopperChristian MarthHeidi FieglAnnemarie WiedemairJulia RösslerJiri HatinaDominik WolfDaniel ReimerAlain G ZeimetPublished in: Journal of cancer research and clinical oncology (2018)
Our study shows that Vav3.1 is not suited as a marker of cancer progression and/or treatment response in endometrial cancer. Feasibility and potential benefit of targeting Vav3.1 in endometrial cancer needs to be evaluated in future studies, proceeding from its clear, roughly ten-fold, induction in the malignant endometrium.